These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8015532)

  • 21. Smoothing effect of a new alpha-glucosidase inhibitor BAY m 1099 on blood glucose profiles of sulfonylurea-treated type II diabetic patients.
    Arends J; Willms BH
    Horm Metab Res; 1986 Nov; 18(11):761-4. PubMed ID: 3539737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of glucosidase inhibitor, Bay g 5421 (acarbose), on the blood glucose in obese diabetic patients ty pe 2 (NIDDM) (author's transl)].
    Laube H; Fouladfar M; Aubell R; Schmitz H
    Arzneimittelforschung; 1980; 30(7):1154-7. PubMed ID: 7191299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses.
    Fischer S; Hanefeld M; Spengler M; Boehme K; Temelkova-Kurktschiev T
    Acta Diabetol; 1998 Apr; 35(1):34-40. PubMed ID: 9625287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of beano on the tolerability and pharmacodynamics of acarbose.
    Lettieri JT; Dain B
    Clin Ther; 1998; 20(3):497-504. PubMed ID: 9663365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group.
    Chan JC; Chan KW; Ho LL; Fuh MM; Horn LC; Sheaves R; Panelo AA; Kim DK; Embong M
    Diabetes Care; 1998 Jul; 21(7):1058-61. PubMed ID: 9653595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of acarbose on blood glucose profiles and plasma 1,5-anhydro-d-glucitol in type 2 diabetes poorly controlled by sulfonylurea therapy.
    Hotta N; Koh N; Sakakibara F; Naruse K; Yamada T; Takeuchi N; Yamada K; Fukasawa H; Kakuta H
    Biomed Pharmacother; 1996; 50(6-7):297-302. PubMed ID: 8952871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44).
    Holman RR; Cull CA; Turner RC
    Diabetes Care; 1999 Jun; 22(6):960-4. PubMed ID: 10372249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes and Acarbose Research Group.
    Costa B; Piñol C
    Diabetes Res Clin Pract; 1997 Oct; 38(1):33-40. PubMed ID: 9347244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes.
    Coniff RF; Shapiro JA; Seaton TB; Hoogwerf BJ; Hunt JA
    Diabetes Care; 1995 Jul; 18(7):928-32. PubMed ID: 7555551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No relationship between carbohydrate intake and effect of acarbose on HbA1c or gastrointestinal symptoms in type 2 diabetic subjects consuming 30-60% of energy from carbohydrate.
    Wolever TM; Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH
    Diabetes Care; 1998 Oct; 21(10):1612-8. PubMed ID: 9773719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effectiveness, safety and epidemiology of the use of acarbose in the treatment of patients with type II diabetes mellitus. A model of medicine-based evidence.
    Scorpiglione N; Belfiglio M; Carinci F; Cavaliere D; De Curtis A; Franciosi M; Mari E; Sacco M; Tognoni G; Nicolucci A
    Eur J Clin Pharmacol; 1999 Jun; 55(4):239-49. PubMed ID: 10424314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.
    Coniff RF; Shapiro JA; Seaton TB; Bray GA
    Am J Med; 1995 May; 98(5):443-51. PubMed ID: 7733122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study.
    Shimabukuro M; Higa N; Chinen I; Yamakawa K; Takasu N
    J Clin Endocrinol Metab; 2006 Mar; 91(3):837-42. PubMed ID: 16368744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late failure of sulphonylurea therapy.
    Standl E; Baumgartl HJ; Füchtenbusch M; Stemplinger J
    Diabetes Obes Metab; 1999 Jul; 1(4):215-20. PubMed ID: 11228756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic effects of acarbose in normal and diabetic rats: long- and short-term administration.
    Hess ME; Haugaard N; Min W; Torbati A
    Arch Int Pharmacodyn Ther; 1986 Sep; 283(1):163-76. PubMed ID: 3800510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus.
    Santeusanio F; Compagnucci P
    Drug Saf; 1994 Dec; 11(6):432-44. PubMed ID: 7727053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study.
    Hotta N; Kakuta H; Sano T; Matsumae H; Yamada H; Kitazawa S; Sakamoto N
    Diabet Med; 1993 Mar; 10(2):134-8. PubMed ID: 8458189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acarbose: its role in the treatment of diabetes mellitus.
    Campbell LK; White JR; Campbell RK
    Ann Pharmacother; 1996 Nov; 30(11):1255-62. PubMed ID: 8913408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of acarbose in the treatment of non-insulin-dependent diabetes mellitus.
    Hanefeld M
    J Diabetes Complications; 1998; 12(4):228-37. PubMed ID: 9647342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. One-year acarbose treatment raises fasting serum acetate in diabetic patients.
    Wolever TM; Radmard R; Chiasson JL; Hunt JA; Josse RG; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH
    Diabet Med; 1995 Feb; 12(2):164-72. PubMed ID: 7743764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.